Litcius/Paper detail

LBA6 KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation

J. Weiß, Rona Yaeger, Melissa L. Johnson, Alexander I. Spira, Samuel J. Klempner, Minal Barve, James G. Christensen, Andrew Chi, Hirak Der‐Torossian, Karen Velastegui, Thian Kheoh, S-H.I. Ou

2021Annals of Oncology74 citationsDOI

Topics & Concepts

CetuximabMedicineColorectal cancerOncologyInternal medicineCancerColorectal Cancer Treatments and StudiesCancer Treatment and PharmacologyPharmacogenetics and Drug Metabolism
LBA6 KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation | Litcius